Neuroendocrine tumors: aspects of diagnosis (literature review)

Main Article Content

A.M. Kvachenyuk
D.A. Kvachenyuk

Abstract

The paper analyzes the literature on the problem of the management of patients with neuroendocrine tumors both from a historical perspective and from a modern aspect. Particular attention is paid to classifications, clinical diagnostic and laboratory diagnostic stages of the management of a patient with neuroendocrine tumors, especially the study of biological markers.

Article Details

How to Cite
Kvachenyuk, A., and D. Kvachenyuk. “Neuroendocrine Tumors: Aspects of Diagnosis (literature Review)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 1, Feb. 2020, pp. 44-49, doi:10.22141/2224-0721.16.1.2020.199127.
Section
Literature Review

References

Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol: 1907. 425–429р.

Padberg B, Schröder S, Capella C, Frilling A, Klöppel G, Heitz PU. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch. 1995;426(6):541–548. doi:10.1007/bf00192107.

Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–597. doi:10.1002/cncr.29099.

Singh S, Granberg D, Wolin E, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol. 2016;3(1):43–53. doi:10.1200/JGO.2015.002980. 

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi:10.1200/JCO.2007.15.4377.

Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol. 1995;144(1):49–59. doi:10.1677/joe.0.1440049.

Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–196. doi:10.1530/ERC-12-0340.

Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1–18. doi:10.1677/erc.0.0110001.

Kulke MH. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat Rev. 2003;29(5):363–370. doi:10.1016/s0305-7372(03)00072-0.

Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer. 2003;10(4):427–436. doi:10.1677/erc.0.0100427.

Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0124884. doi:10.1371/journal.pone.0124884. 

Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–422. doi:10.1007/s00259-002-1050-8.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S–6S.

Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–e446. doi:10.1016/S1470-2045(15)00186-2.

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–712. doi:10.1097/MPA.0b013e3181ec124e.

O'Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194–202. doi:10.1159/000225948.

Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33(16):1855–1863. doi:10.1200/JCO.2014.60.2532.

McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23nd ed. Louis, Missouri: Elsevier; 2016. 1584p.

Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39(10):969–973. doi:10.1080/00365520410003362.

Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17(9):2427–2443. doi:10.1245/s10434-010-1006-3.